Daiichi Sankyo Daichirona for intramuscular injection for booster vaccination approved in Japan as Omicron XBB.1.5-adapted Monovalent mRNA Vaccine against COVID Ruchika Sharma28 Nov 2023 2:30 PM ISTTokyo: Daiichi Sankyo has announced that DAICHIRONA FOR INTRAMUSCULAR INJECTION (DS-5670) for booster vaccination has been approved in Japan as an ...
IHH healthcare unit drags Daiichi Sankyo to court over Fortis Healthcare deal, claims 20 billion yen as damages Ruchika Sharma16 Nov 2023 2:30 PM ISTNTK is also seeking an injunction to prevent Daiichi from making defamatory remarks against it with respect to the aforesaid open offers, it noted.
Daiichi Sankyo Vanflyta approved in EU as First FLT3 Inhibitor specifically for newly Diagnosed FLT3-ITD Positive AML Ruchika Sharma13 Nov 2023 4:30 PM ISTTokyo: Daiichi Sankyo’s VANFLYTA (quizartinib) has been approved in the European Union (EU) for use in combination with standard cytarabine and ...
AstraZeneca-Daiichi Sankyo Enhertu approved in EU for lung cancer Ruchika Sharma24 Oct 2023 1:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the...
Merck-Daiichi Sankyo ink pact for patritumab deruxtecan,ifinatamab deruxtecan, raludotatug deruxtecan Ruchika Sharma22 Oct 2023 1:45 PM ISTDesigned using Daiichi Sankyo's proprietary DXd ADC technology to target and deliver a cytotoxic payload inside cancer cells that express a specific...
AstraZeneca Enhertu recommended for nod in EU by CHMP for HER2-mutant advanced non-small cell lung cancer Ruchika Sharma16 Sept 2023 1:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for...
Daiichi Sankyo DS-3939 enters clinical development in patients across several types of advanced solid cancers Ruchika Sharma10 Sept 2023 3:54 PM ISTTokyo: Daiichi Sankyo has announced that the first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS-3939 in patients with...
Daiichi Sankyo submits sNDA for Omicron XBB.1.5-adapted COVID vaccine in Japan Ruchika Sharma10 Sept 2023 10:00 AM ISTTokyo: Daiichi Sankyo has announced that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and...
AstraZeneca-Daiichi Sankyo Enhertu gets two breakthrough therapy designations in US for multiple HER2 expressing cancers Ruchika Sharma3 Sept 2023 4:00 PM ISTTokyo: Daiichi Sankyo has announced that ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations...
Daiichi Sankyo Enhertu approved in Japan as first HER2 directed therapy for patients with HER2 mutant metastatic lung cancer Ruchika Sharma25 Aug 2023 10:00 AM ISTTokyo: Daiichi Sankyo has announced that ENHERTU (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with...
Daiichi Sankyo to close Japanese RnD subsidiary Daiichi Sankyo RD Novare Ruchika Sharma8 Aug 2023 4:30 PM ISTTokyo: Daiichi Sankyo has announced that it has decided to close its Japanese research and development (R&D) subsidiary, Daiichi Sankyo RD Novare...
Daiichi Sankyo Daichirona for Intramuscular Injection approved for manufacturing, marketing as booster vaccination in Japan Ruchika Sharma2 Aug 2023 1:30 PM ISTDAICHIRONA for Intramuscular Injection is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain of the...
